Skin Cancer Treatment Market By Type, By Therapy, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

Description

List of Tables

Skin cancer is common type of cancer caused due to sun's harmful radiation. The abnormal pigmentation, collagenosis, skin wrinkling, and solar keratosis on sun-exposed skin are the signs associated with skin cancer. There are two types of skin cancers including melanoma and non-melanoma. There are two types of non-melanoma cancers which includes basal cell carcinoma and squamous cell carcinoma. Non-melanocytic skin cancer is the most prevalent type of skin cancer detected in people which affects over 2-3 million people worldwide. There are several medicated treatments available for skin cancer which includes targeted therapy, chemotherapy, and immunotherapy.

Increase in prevalence of non-melanoma and melanoma type of skin cancer across the globe, availability of various skin cancer treatments, and increased demand for skin cancer treatment are the factors that positively influence the skin cancer treatment market growth. For instance, according to the American Cancer Society, in 2020, 5.4 million people were diagnosed with basal and squamous skin cancer in the U.S. each year and there are 2,000 people die with same cancer. As per the same source, estimated number of people suffering from basal and squamous skin cancer in U.S. is 3.3 million. The most common type of skin cancer frequently observed in American people is basal cell cancer with 8 out of 10 people. Squamous cell cancer is less likely observed in American people. In addition, initiatives taken by governments for the management of skin cancer and key players involved in the manufacturing and development of the advanced therapies for the effective skin cancer treatment are the factor boost skin cancer treatment market. For instance, in 2020, Novartis AG announced COMBI-AD clinical trial for the products Tafinlar + Mekinist to treat stage III BRAF V600-mutated melanoma patients to provide surgery to provide efficient, long-term effect for those patients who have high risk of cancer recurrence. In addition, availability of hospital pharmacies and drugs, diagnostic centers and hospitals influence the market growth. However, side effects associated with use of chemotherapy and radiotherapy skin cancer treatment restrain the market growth. Rise in number of product approvals and emergence of advanced therapies for skin cancer treatment are opportunities for the market growth.

The global skin cancer treatment market is segmented on the basis of type, therapy, distribution channel, and region. By type, the market is classified into melanoma and non-melanoma. The non-melanoma segment is further segmented into basal cell carcinoma, squamous cell carcinoma, and others. By therapy, the market is classified into immunotherapy, targeted therapy, and chemotherapy. By distribution channel, it is classified into hospitals pharmacies, drug stores & retail pharmacies, and online providers. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global skin cancer treatment market are Amgen Inc, Bristol Myers Squibb Company, F. Hoffman-La-Roche Ltd, GlaxoSmithKline Plc., LEO Pharm A/S, Merck KGAA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals and, Sun Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the skin cancer treatment market analysis from 2021 to 2031 to identify the prevailing skin cancer treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the skin cancer treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global skin cancer treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Distribution Channel

Hospitals Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

By Type

Melanoma
Non-Melanoma
- Type
- Basal Cell Carcinoma
- Squamous Cell Carcinoma
- Others

By Therapy

Immunotherapy
Targeted Therapy
Chemotherapy

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest Of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
Key Market Players
- Amgen Inc.
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Glaxosmithkline plc
- LEO Pharma
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Sun Pharmaceutical Industries Ltd.

Product Code: A17526

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape

CHAPTER 4: SKIN CANCER TREATMENT MARKET, BY TYPE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Melanoma
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Non-Melanoma
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.3.4 Non-Melanoma Skin Cancer Treatment Market by Type
  - 4.3.4.1 Basal Cell Carcinoma Market size and forecast, by region
  - 4.3.4.2 Squamous Cell Carcinoma Market size and forecast, by region
  - 4.3.4.3 Others Market size and forecast, by region

CHAPTER 5: SKIN CANCER TREATMENT MARKET, BY THERAPY

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Immunotherapy
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Targeted Therapy
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
5.4 Chemotherapy
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country

CHAPTER 6: SKIN CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Hospitals Pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Drug Stores and Retail Pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Online Providers
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country

CHAPTER 7: SKIN CANCER TREATMENT MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Type
  - 7.2.2.1 North America Non-Melanoma Skin Cancer Treatment Market by Type
- 7.2.3 North America Market size and forecast, by Therapy
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Type
  - 7.2.5.1.2 Market size and forecast, by Therapy
  - 7.2.5.1.3 Market size and forecast, by Distribution Channel
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Type
  - 7.2.5.2.2 Market size and forecast, by Therapy
  - 7.2.5.2.3 Market size and forecast, by Distribution Channel
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Type
  - 7.2.5.3.2 Market size and forecast, by Therapy
  - 7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Type
  - 7.3.2.1 Europe Non-Melanoma Skin Cancer Treatment Market by Type
- 7.3.3 Europe Market size and forecast, by Therapy
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Type
  - 7.3.5.1.2 Market size and forecast, by Therapy
  - 7.3.5.1.3 Market size and forecast, by Distribution Channel
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Type
  - 7.3.5.2.2 Market size and forecast, by Therapy
  - 7.3.5.2.3 Market size and forecast, by Distribution Channel
  - 7.3.5.3 UK
  - 7.3.5.3.1 Market size and forecast, by Type
  - 7.3.5.3.2 Market size and forecast, by Therapy
  - 7.3.5.3.3 Market size and forecast, by Distribution Channel
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Type
  - 7.3.5.4.2 Market size and forecast, by Therapy
  - 7.3.5.4.3 Market size and forecast, by Distribution Channel
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Type
  - 7.3.5.5.2 Market size and forecast, by Therapy
  - 7.3.5.5.3 Market size and forecast, by Distribution Channel
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Type
  - 7.3.5.6.2 Market size and forecast, by Therapy
  - 7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Type
  - 7.4.2.1 Asia-Pacific Non-Melanoma Skin Cancer Treatment Market by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Therapy
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Type
  - 7.4.5.1.2 Market size and forecast, by Therapy
  - 7.4.5.1.3 Market size and forecast, by Distribution Channel
  - 7.4.5.2 China
  - 7.4.5.2.1 Market size and forecast, by Type
  - 7.4.5.2.2 Market size and forecast, by Therapy
  - 7.4.5.2.3 Market size and forecast, by Distribution Channel
  - 7.4.5.3 India
  - 7.4.5.3.1 Market size and forecast, by Type
  - 7.4.5.3.2 Market size and forecast, by Therapy
  - 7.4.5.3.3 Market size and forecast, by Distribution Channel
  - 7.4.5.4 Australia
  - 7.4.5.4.1 Market size and forecast, by Type
  - 7.4.5.4.2 Market size and forecast, by Therapy
  - 7.4.5.4.3 Market size and forecast, by Distribution Channel
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Type
  - 7.4.5.5.2 Market size and forecast, by Therapy
  - 7.4.5.5.3 Market size and forecast, by Distribution Channel
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Type
  - 7.4.5.6.2 Market size and forecast, by Therapy
  - 7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Type
  - 7.5.2.1 LAMEA Non-Melanoma Skin Cancer Treatment Market by Type
- 7.5.3 LAMEA Market size and forecast, by Therapy
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Type
  - 7.5.5.1.2 Market size and forecast, by Therapy
  - 7.5.5.1.3 Market size and forecast, by Distribution Channel
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Type
  - 7.5.5.2.2 Market size and forecast, by Therapy
  - 7.5.5.2.3 Market size and forecast, by Distribution Channel
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Type
  - 7.5.5.3.2 Market size and forecast, by Therapy
  - 7.5.5.3.3 Market size and forecast, by Distribution Channel
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Type
  - 7.5.5.4.2 Market size and forecast, by Therapy
  - 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Amgen Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Bristol-Myers Squibb
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 F. Hoffmann-La Roche
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Glaxosmithkline plc
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 LEO Pharma
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 Merck KGaA
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Novartis AG
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Pfizer Inc.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Regeneron Pharmaceuticals, Inc.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Sun Pharmaceutical Industries Ltd.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments